Abolfazl Razzaghdoust1, Bahram Mofid2,3,4, Maryam Moghadam5. 1. Urology and Nephrology Research Center, Student Research Committee, Shahid Beheshti University of Medical Sciences, Tehran, Iran. 2. Cancer Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran. mofid429@sbmu.ac.ir. 3. School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran. mofid429@sbmu.ac.ir. 4. Department of Radiation Oncology, Shohada-e-Tajrish Medical Center, Shahid Beheshti University of Medical Sciences, Shahrdari St, Tajrish Sq, Tehran, 1989934148, Iran. mofid429@sbmu.ac.ir. 5. Department of Radiation Oncology, Shohada-e-Tajrish Medical Center, Shahid Beheshti University of Medical Sciences, Shahrdari St, Tajrish Sq, Tehran, 1989934148, Iran.
Abstract
PURPOSE: Neutropenic complications remain the major dose-limiting toxicities of cancer chemotherapy. The aim of this study was to develop and internally validate a comprehensive and easily measurable scoring system for prediction of severe or febrile neutropenia in the first chemotherapy cycle of patients with solid tumors or lymphoma. METHODS: This prospective cohort study included consecutive patients at a tertiary referral hospital. Many clinical and laboratory-independent variables were measured at baseline. A multivariable logistic regression analysis was applied after unadjusted analysis, and the multivariable model was transformed into a simplified risk score based on 6 bootstrapped regression coefficients. The simplified scoring system was internally validated using cross-validation. All statistical tests were two-sided. RESULTS: A total of 305 patients were enrolled and followed during 1732 chemotherapy cycles. Of these, 259 were eligible for analysis. The multivariable model revealed 6 predictive factors for severe or febrile neutropenia (scores in parentheses): high-risk regimen without colony-stimulating factor (4 points), intermediate-risk regimen without colony-stimulating factor (3 points), age > 65 years and elevated ferritin (3 points), body mass index < 23 kg/m2 and body surface area < 2 m2 (2 points), estimated glomerular filtration rate < 60 mL/min/1.73m2 (2 points), and elevated C-reactive protein (1 point). The receiver operating characteristic curve was 0.832 (95% confidence interval [Cl], 0.767-0.897) for the simplified model and 0.816 (95% Cl, 0.771-0.860) for the cross-validation. CONCLUSIONS: We developed and internally validated a user-friendly prediction model to guide personalized decision-making using available clinical data and few cost-effective laboratory tests. External validation in other centers with different patients is required.
PURPOSE:Neutropenic complications remain the major dose-limiting toxicities of cancer chemotherapy. The aim of this study was to develop and internally validate a comprehensive and easily measurable scoring system for prediction of severe or febrile neutropenia in the first chemotherapy cycle of patients with solid tumors or lymphoma. METHODS: This prospective cohort study included consecutive patients at a tertiary referral hospital. Many clinical and laboratory-independent variables were measured at baseline. A multivariable logistic regression analysis was applied after unadjusted analysis, and the multivariable model was transformed into a simplified risk score based on 6 bootstrapped regression coefficients. The simplified scoring system was internally validated using cross-validation. All statistical tests were two-sided. RESULTS: A total of 305 patients were enrolled and followed during 1732 chemotherapy cycles. Of these, 259 were eligible for analysis. The multivariable model revealed 6 predictive factors for severe or febrile neutropenia (scores in parentheses): high-risk regimen without colony-stimulating factor (4 points), intermediate-risk regimen without colony-stimulating factor (3 points), age > 65 years and elevated ferritin (3 points), body mass index < 23 kg/m2 and body surface area < 2 m2 (2 points), estimated glomerular filtration rate < 60 mL/min/1.73m2 (2 points), and elevated C-reactive protein (1 point). The receiver operating characteristic curve was 0.832 (95% confidence interval [Cl], 0.767-0.897) for the simplified model and 0.816 (95% Cl, 0.771-0.860) for the cross-validation. CONCLUSIONS: We developed and internally validated a user-friendly prediction model to guide personalized decision-making using available clinical data and few cost-effective laboratory tests. External validation in other centers with different patients is required.
Authors: Arti Hurria; Anju Hurria; Kelly Brogan; Katherine S Panageas; Carol Pearce; Larry Norton; Ann Jakubowski; Jane Howard; Clifford Hudis Journal: Drugs Aging Date: 2005 Impact factor: 3.923
Authors: J Alexandre; E Rey; V Girre; S Grabar; A Tran; V Montheil; F Rabillon; V Dieras; V Jullien; P Hérait; G Pons; J-M Treluyer; F Goldwasser Journal: Ann Oncol Date: 2006-10-23 Impact factor: 32.976
Authors: M Aapro; H Ludwig; C Bokemeyer; P Gascón; M Boccadoro; K Denhaerynck; A Krendyukov; M Gorray; K MacDonald; I Abraham Journal: Ann Oncol Date: 2016-11 Impact factor: 32.976
Authors: Jan P Vandenbroucke; Erik von Elm; Douglas G Altman; Peter C Gøtzsche; Cynthia D Mulrow; Stuart J Pocock; Charles Poole; James J Schlesselman; Matthias Egger Journal: PLoS Med Date: 2007-10-16 Impact factor: 11.069
Authors: Razan Zatarah; Nour Faqeer; Tasnim Quraan; Aseel Mahmoud; Lujain Matalka; Lana Abu Khadija; Aya Kamal; Dalia Rimawi Journal: JNCI Cancer Spectr Date: 2022-05-02
Authors: Theis Aagaard; Ashley Roen; Joanne Reekie; Gedske Daugaard; Peter de Nully Brown; Lena Specht; Henrik Sengeløv; Amanda Mocroft; Jens Lundgren; Marie Helleberg Journal: JNCI Cancer Spectr Date: 2018-11-29
Authors: Evelin Bachmeier; María Elena Migueles Goitea; Jorge Alberto Linares; Fernando Martin Wietz; Sol Jarchum; Gustavo Jarchum; Mabel Noemi Brunotto; Marcelo Adrian Mazzeo Journal: Rev Fac Cien Med Univ Nac Cordoba Date: 2021-12-28